San Francisco, May 31, 2023 – Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced closings of its Series C financing round.
This financing and closings includes existing shareholders as well as new undisclosed investors. The current proceeds will be used to complete the global pivotal Phase 3 study for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. The financing will also support the therapeutic and regional expansion of Recardio.
“The coming years will be exciting for Recardio as we are starting our global pivotal Phase 3 trial with Dutogliptin in AMI, one of the most promising indications from our cardiovascular platform technology” said Dr. Roman Schenk, Recardio’s founder, President and Executive Chairman.
Recardio’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases.
Recardio Inc. is a late-stage clinical life science company focusing on therapies for cardiovascular and other diseases.
The company is located in San Francisco, California, having its operations in USA and Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated pre- and clinically significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardiac tissue after an injury.
After receiving FDA and EMA approval, Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in earlier clinical and preclinical stage.